Subtalar Arthrodesis for Calcaneus Fractures
Trial Summary
What is the purpose of this trial?
Management of severe injuries to the heel (displaced intra-articular calcaneus fractures) continues to be a major challenge for orthopedic surgeons. Previous studies have demonstrated poor outcomes, and results show that patients experience long-term pain and decreased quality of life postoperatively. Poor outcomes are driven by pain, in particular, which is linked to post-traumatic subtalar arthritis.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of the treatment Subtalar Arthrodesis for Calcaneus Fractures?
Research shows that primary subtalar arthrodesis can be effective for treating severe calcaneus fractures, with most patients achieving bone healing within 8 to 12 weeks and many returning to work. Additionally, subtalar arthrodesis has been successful in improving pain and function in patients with subtalar arthritis, with a high satisfaction rate among patients.12345
How is primary subtalar arthrodesis different from other treatments for calcaneus fractures?
Primary subtalar arthrodesis is unique because it involves fusing the subtalar joint (the joint below the ankle) to treat severe calcaneus (heel bone) fractures, restoring bone height and width with bone grafts and screws. This approach is particularly beneficial for patients with complex fractures, allowing many to return to work and daily activities, unlike other treatments that may not address severe cases as effectively.12346
Research Team
Joseph R Hsu, MD
Principal Investigator
Wake Forest University Health Sciences
Eligibility Criteria
This trial is for adults over 18 with severe heel bone fractures (Sanders III/IV or Sanders II with specific complications). Participants must be undergoing surgery, able to attend follow-ups for a year, and speak English or Spanish. It's not for those using certain surgical methods, under 18, very overweight (BMI >40), unable to commit to follow-up visits, or prisoners.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo surgical treatment with either ORIF + PSTA or ORIF alone
Follow-up
Participants are monitored for safety, effectiveness, and recovery progress
Outcome Assessment
Assessment of primary and secondary outcomes including return to work, pain levels, and functional recovery
Treatment Details
Interventions
- Primary Subtalar Arthrodesis
Find a Clinic Near You
Who Is Running the Clinical Trial?
Wake Forest University Health Sciences
Lead Sponsor